Gkolfinopoulos Stavros, Tsapakidis Konstantinos, Papadimitriou Konstantinos, Papamichael Demetris, Kountourakis Panteleimon
Stavros Gkolfinopoulos, Demetris Papamichael, Panteleimon Kountourakis, Department of Medical Oncology, BOC Oncology Center, 2006 Strovolos, Nicosia, Cyprus.
World J Methodol. 2017 Mar 26;7(1):9-15. doi: 10.5662/wjm.v7.i1.9.
Chromogranin A, due to its primary expression throughout the neuroendocrine system, is a widely accepted biomarker for the assessment of neuro-endocrine tumors. It has been traditionally used in the management of patients with tumors of gastro-enteropancreatic origin. Lately, it has also been implicated in various conditions and diseases, both benign and malignant. However, the paucity of data of adequate strength, as well as its relation with common physiologic conditions and its interaction with commonly prescribed medications, limit its clinical use in only a narrow spectrum. Herein, we present a thorough review to the most frequent conditions where its levels are affected, focusing specifically on its potential use as a prognostic and predictive biomarker in oncology.
嗜铬粒蛋白A因其主要在整个神经内分泌系统中表达，是评估神经内分泌肿瘤广泛认可的生物标志物。它传统上用于胃肠胰源性肿瘤患者的管理。最近，它也与各种良性和恶性病症及疾病有关。然而，缺乏足够有力的数据，以及它与常见生理状况的关系及其与常用药物的相互作用，将其临床应用限制在很窄的范围内。在此，我们对其水平受影响的最常见情况进行全面综述，特别关注其在肿瘤学中作为预后和预测生物标志物的潜在用途。
